AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease.
Sign Up to like & getrecommendations! Published in 2025 at "Gastroenterology"
DOI: 10.1053/j.gastro.2025.09.038
Abstract: BACKGROUND & AIMS This American Gastroenterological Association (AGA) living guideline is intended to support practitioners in the pharmacologic management of moderate-to-severely active Crohn's disease (CD). METHODS A multidisciplinary panel of clinical experts and methodologists used… read more here.
Keywords: efficacy medication; suggests using; moderate severely; pharmacologic management ... See more keywords
OP12 Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trial
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.0012
Abstract: Mirikizumab (miri), an anti-IL-23p19 antibody, is approved for the treatment of ulcerative colitis and under development for Crohn’s disease (CD). We investigated how miri impacted fatigue, bowel urgency, and health-related quality of life (HRQoL) through… read more here.
Keywords: moderately severely; disease; urgency; severely active ... See more keywords
OP23 Guselkumab induction restores intestinal immune homeostasis and promotes epithelial repair in moderately to severely active Ulcerative Colitis
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.0023
Abstract: Selective inhibition of interleukin-23 (IL-23) through antagonism of the IL-23p19 subunit has demonstrated clinical efficacy in inflammatory bowel disease, but the mechanism of action (MoA) has not been fully defined. Here we provide a detailed… read more here.
Keywords: moderately severely; active ulcerative; cell; severely active ... See more keywords
P759 Understanding how patients with moderate-to-severe Crohn’s disease describe the spectrum of bowel urgency definitions: Results from qualitative research
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.0889
Abstract: The objective of this study was to understand how adult patients with moderately-to-severely active Crohn’s disease (CD) describe bowel urgency (BU) remission and “no or minimal” BU. Qualitative phone interviews were conducted with adults with… read more here.
Keywords: moderately severely; crohn disease; crohn; urgency ... See more keywords
P1018 Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with moderately to severely active Ulcerative Colitis
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.1148
Abstract: Risankizumab (RZB) has been evaluated in subjects with moderately to severely active ulcerative colitis (UC) in the INSPIRE and COMMAND trials. Population pharmacokinetic (PPK) and exposure-response (ER) analyses were conducted at the end of Phase… read more here.
Keywords: week; moderately severely; exposure; efficacy ... See more keywords
P0670 Efficacy of subcutaneous guselkumab induction therapy by baseline demographics and concomitant medications in participants with moderately to severely active Crohn’s disease: Results from the phase 3 GRAVITI study
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjae190.0844
Abstract: The GRAVITI study established the efficacy and safety of subcutaneous (SC) induction with guselkumab (GUS), a dual-acting IL-23p19 subunit inhibitor, in participants (pts) with moderately to severely active Crohn’s disease (CD) through 48 weeks of… read more here.
Keywords: week; disease; moderately severely; response ... See more keywords
P1111 Infliximab is not Superior to Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colotis with PR3-ANCA Positive : A Retrospective Multicentre Real-World Study
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjae190.1285
Abstract: Current literature presents conflicting findings about the efficacy of Infliximab (IFX) versus vedolizumab (VDZ) in patients with moderately to severely active ulcerative colitis (UC). Patients with UC who are positive for anti-neutrophil cytoplasmic antibodies(ANCA) are… read more here.
Keywords: moderately severely; vdz; response; severely active ... See more keywords
Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2017 at "Health and Quality of Life Outcomes"
DOI: 10.1186/s12955-017-0813-7
Abstract: BackgroundTo assess the measurement properties of two single-item patient-reported outcome (PRO) measures that assessed the length of time (in minutes) and severity of morning joint stiffness (MJS) experienced each day.MethodsData from two Phase 3, randomized… read more here.
Keywords: severity mjs; severely active; duration; mjs ... See more keywords
Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and Experimental Gastroenterology"
DOI: 10.2147/ceg.s367086
Abstract: Abstract This review addresses appropriate patient selection for upadacitinib, a Janus kinase inhibitor approved by the FDA and EMA for treatment of moderately to severely active ulcerative colitis (UC). Janus kinase molecules can contribute to the… read more here.
Keywords: patient selection; active ulcerative; severely active; ulcerative colitis ... See more keywords
Therapeutic Potential of Etrasimod in the Management of Moderately-to-Severely Active Ulcerative Colitis: Evidence to Date
Sign Up to like & getrecommendations! Published in 2024 at "Clinical and Experimental Gastroenterology"
DOI: 10.2147/ceg.s391706
Abstract: Abstract Etrasimod is a sphingosine 1 phosphate (S1P) receptor modulator approved for the treatment of moderate to severely active ulcerative colitis (UC). Etrasimod selectively activates S1P1,4,5 receptors with no detectable activity on S1P2,3. The ELEVATE… read more here.
Keywords: active ulcerative; therapeutic potential; etrasimod; ulcerative colitis ... See more keywords
Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis in induction and maintenance: systematic literature review and Bayesian network meta-analysis
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Comparative Effectiveness Research"
DOI: 10.57264/cer-2024-0225
Abstract: Aim: Several therapies have recently been licensed for the treatment of patients with moderately to severely active ulcerative colitis (UC). To provide comparative evidence of newly available treatments, Bayesian network meta-analyses were conducted to compare… read more here.
Keywords: moderately severely; maintenance; efficacy; severely active ... See more keywords